Company intelligence / Profile preview

Cytune Pharma

Nantes, Pays de la Loire, France

Ownership: Private
Employees: ~2
Development stage: Other

Overview

SO-C101 (formerly CYP 0150/RLI-15), an IL-15 superagonist fusion protein, showed interim Phase 1/1b data as monotherapy and with pembrolizumab in advanced/metastatic solid tumors; preclinical data supports immune effector cell stimulation without T regulatory expansion.

Therapeutic areas: Oncology
Modalities: Fusion proteinImmunocytokine
Industry: Biotech

Partnerships

SOTIO

Beyond the preview

Go deeper on Cytune Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytune Pharma.

Explore the full profile